In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedImmune LLC

http://www.medimmune.com

Latest From MedImmune LLC

Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies

Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.

Deal Watch Business Strategies

BioAge Puts VC Muscle Behind Phase II Azelaprag Trials In Obesity

The company completed a $170m series D round and plans to start trials combining the drug with GLP-1 agonists like Eli Lilly’s Zepbound in mid-2024.

Financing StartUps and SMEs

Gilead Touts Catalyst-Rich 2024 Amid Sales Slump

The drug maker pointed to a variety of key trial readouts over the course of the year, including the pivotal study of its long-acting HIV PrEP injectable and Phase III updates for Trodelvy.

Sales & Earnings Companies

Focus On Execution Pays Off Across Bristol’s New Product Portfolio

BMS reiterated its 2024 focus on execution across its portfolio and R&D pipeline as it works through upcoming losses of exclusivity, and its fourth quarter revenues reflected year-end efforts to drive sales.

Launches Growth
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register